Top Markets
#1 Akedo Akedo +62.25%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.06%
#4 Velvet Velvet +40.81%
#5 Black Phoenix Black Phoenix +34.48%
#6 Ο„emplar Ο„emplar +28.04%
#7 Ribbita by Virtuals Ribbita by Virtuals +20.04%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.68%
#9 Bitway Bitway +17.34%
#10 Cap Cap +16.41%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Nutroganics, Inc. Nutroganics, Inc.

Nutroganics, Inc.

NUTTQ
Rank in Stocks #38311
Nutroganics, Inc.'s primary business strategy involved acquiring and overseeing... Nutroganics, Inc.'s primary business strategy involved acquiring and overseeing profitable companies within the healthy lifestyle industry, focusing heavily on nutritional supplements and the natural and organic food markets. One of its key operational entities was Silverbow Honey Company, a subsidiary that handled the production, packaging, and sale of various honey products. These goods were supplied to food manufacturers and prominent national grocery chains, marketed under both the Silverbow brand and as private label offerings. The company was based in Bethesda, Maryland. However, a significant development occurred on October 14, 2016, when Nutroganics, Inc. and its affiliated organizations filed a voluntary petition for Chapter 7 liquidation with the US Bankruptcy Court for the District of Delaware.
Share Price
$0.00001
Last synced: 2025-05-07
Market Cap
$1.07M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Nutroganics, Inc. (NUTTQ)

Category

Healthcare
P/E ratio for Nutroganics, Inc. (NUTTQ)
P/E ratio as of 2026 TTM: 0
According to Nutroganics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Nutroganics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 23.71 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 220.17 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.